Formulary Monographs [CYPROTERONE, 1000]
|
|
CYPROTERONE
|
|
|
|
|
|
ANTINEOPLASTICS
|
|
|
Advanced prostatic carcinoma.
|
|
|
Impotence, inhibition of spermatogenesis, headache, gynecomastia,
galactorrhea, weight gain, lipid abnormalities, gastrointestinal disturbances and anemia. Several cases of hep ato-toxicity , fluid retention, venous thromboembolism, my ocardial ischemia, breathlessness and cerebrovascular accidents has occurred in 10% of prostate cancer patients treated with the drug. |
|
|
Palliative treatment: 200- 300 mg daily in 2 or 3 divided doses after meals. S uppression of disease flare: 100 mg twice daily used alone for 5 to 7 day s, then with a gonadorelin analogue for 3 to 4 weeks.
|
|
|
|
|
|
Use of cyproterone during pregnancy might carry a risk of feminisation of a male fetus.
|
|
|
|
|
|
|